Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
Gilead Sciences announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based innovation, affordability, and global health leadership.
As part of the three-year agreement, Gilead addresses all requests by President Trump to implement a new pricing strategy that prioritizes American patients, ensuring the U.S. no longer bears a disproportionate share of global healthcare costs.
This includes:
- Discounts on certain existing medicines within the U.S. Medicaid program, similar to what is paid in comparably developed nations, including select medications to treat HIV, hepatitis C, hepatitis B and COVID-19.
- Pricing future medicines at parity with other key developed nations.
- Launching a Direct-to-Patient Program where individuals with a prescription can obtain Gilead’s hepatitis C treatment and cure, Epclusa ®, at a discounted cash price. Gilead will make Epclusa available via TrumpRx.gov where American patients can be connected directly with Gilead’s Direct-to-Patient Program.
- An agreement with the U.S. Department of Commerce to be exempt from Section 232 pharmaceutical tariffs for three years, provided Gilead further invests in manufacturing in the United States.
Based on these terms, the company expects the financial impact to be manageable in 2026 and beyond. Additional terms of the agreement with the U.S. government remain confidential.
This agreement reinforces America’s leadership in global health and biomedical innovation and builds upon Gilead’s recently announced landmark partnership with the U.S. Department of State to provide its breakthrough HIV prevention medicine, lenacapavir, at no profit to up to two million individuals in the most severely affected countries around the world over the next three years.
Gilead also recently announced it will invest $32 billion in U.S.-based manufacturing, R&D, and infrastructure over the next five years. This investment is projected to generate $43 billion in national economic value and create more than 3,000 direct and indirect jobs.